| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e799f38b39b34f5266edfa3f07f7df45
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ab3413f8184feb74be59b7ed962a5b97
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_140cbf2711a373d4902342fe0e673a75 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2002-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-815
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L33-105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-815
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-10 |
| filingDate |
2016-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c246b190ec377d3260ec8a9090a99a21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_581b8e67d498ab7d75728ce9e8d412cf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_168fcdd5fb103e97769e1010f10fb854
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_67d11a13778d2b9c0608c1206e314a1b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_55b401c39737712c38c1a2b5ddb70441
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ee625df5f6a3808bd0c3c91f3ff4a5a2 |
| publicationDate |
2018-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2018214471-A1 |
| titleOfInvention |
Composition for preventing and treating osteoporosis, comprising dihydrophaseic acid 3-o-b-d-glucopyranoside isolated from lycium root bark extracts |
| abstract |
The present invention relates to a compound of dihydrophaseic acid 3′-O-beta-D-glucopyranoside for the prevention and treatment of osteoporosis. It was found that the D3G isolated from the lycium root bark extract induces the activity of osteoblast differentiation while promoting the proliferation of pre-osteoblast, and promotes the bone remodeling by promoting the differentiation of both osteoblast and osteoclast when mixing and culturing pre-osteoblast which is the precursor of osteoblast, and monocyte which is the precursor of osteoclast. Therefore, the D3G of the present invention is expected to be useful as a pharmacological agent or functional food effective for the prevention and treatment of osteoporosis which is a disease caused by the abnormal balance of bone remodeling, |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113181195-A |
| priorityDate |
2015-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |